查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715464

口服蛋白質和胜肽市場按產品類型、配方、開發階段、應用和最終用戶分類—2025-2030 年全球預測

Oral Proteins & Peptides Market by Product Type, Formulation, Development Stage, Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023 年口服蛋白質和胜肽市場價值為 61 億美元，預計 2024 年將達到 68.9 億美元，預計到 2030 年將以 13.27% 的複合年成長率成長，達到 146 億美元。

主要市場統計數據
基準年2023年 61億美元
預計年份：2024年 68.9億美元
預測年份 2030 146億美元
複合年成長率（%） 13.27%

口服蛋白質和胜肽已成為不斷發展的治療領域的焦點，為疾病管理和患者依從性提供了變革性的好處。近年來，生物技術和製劑科學的重大進步為這些分子超越傳統管理障礙鋪平了道路。人們越來越重視開發強大的口服給藥系統，不僅可以確保生物有效性，還可以提高患者的舒適度和依從性。隨著研究的深入和技術的發展，市場正在吸引製藥開發商、醫療保健提供者和投資者的注意。

這份全面的評論詳細介紹了當前的市場狀況，並提供了對其未來成長軌蹟的見解。確定關鍵趨勢，探索創新制定策略，並評估法規結構對市場成長的影響。此項分析是在技術快速進步和全球追求更有效、以患者為中心的護理的環境下組裝的。本文針對的是那些致力於以證據為基礎的決策和策略性市場介入的相關人員。隨著患者需求的不斷變化，口服蛋白質和胜肽市場將迎來顛覆性突破，重新定義治療模式並最佳化治療結果。

從策略角度來看，這本書是一個寶貴的知識中心，提供數據支援的見解和深入的定性分析，有助於闡明市場趨勢。提供的見解重點在於臨床進步和市場策略的整合，以解決未滿足的醫療需求。最終，這些見解的綜合凸顯了在高度互聯的市場中協調研究、創新和商業化活動的重要性，為轉型之旅奠定了基礎。

不斷變化的市場條件及其策略影響

過去幾年，在科學快速突破和全球醫療保健重點重新調整的推動下，口服蛋白質和胜肽市場發生了變革性的變化。藥物輸送系統的最新創新透過引入有效結合便利性和有效性的有前景的替代方案，挑戰了長期以來對腸外給藥的依賴。這一演變的基礎是重新關注以患者為中心的方法、先進的生物技術以及研究機構和製藥公司之間的戰略夥伴關係。

新型封裝技術的出現、胜肽穩定性的提高以及增強口服吸收的改進是這項轉變的核心要素。監管機構也不斷調整其框架以適應突破性療法，從而加快核准並創造更有利於創新的環境。隨著這些技術進步，市場相關人員已經開始轉變策略，轉向開發既能滿足臨床需求又能實現經濟永續性的綜合解決方案。決策者現在正在使用預測分析、巨量資料和基於風險的監控來簡化開發平臺，同時最大限度地縮短產品上市時間。

此外，市場在全球投資流向方面正在經歷重大調整，更加注重瞄準新興治療領域和服務不足的患者群體。因此，傳統市場相關人員被迫重新思考其商業框架，並追求動態且靈活的經營模式。這種轉變不僅僅是一種漸進的改進，而是一種範式轉變，它將重新定義競爭策略並塑造新的臨床價值提案。在這種環境下，採取積極主動的方法，並以紮實的研究和無縫的執行為後盾，對於獲得這些轉型變革的好處至關重要。

影響產品開發和市場策略的關鍵細分洞察

對市場區隔的細緻了解有助於制定口服蛋白質和胜肽領域的策略規劃和產品開發。我們從多個維度對市場進行了嚴格分析，每個維度都為我們提供有關市場結構和成長潛力的關鍵見解。首先，根據產品類型，我們區分基於胰島素的蛋白質和胜肽療法。此外，在此類別中，已確定了組合胰島素、長效胰島素類似物、速效胰島素類似物和重組人類胰島素等子區隔，以及與抑鈣素為基礎的療法、Glucagon-Like Peptide-1受體促效劑和加壓素類似物相對應的部分。這種詳細的細分有助於深入了解治療效果、市場滲透和創新趨勢。

市場還根據配方進行細分，提供膠囊、液體、粉末和錠劑等各種選擇，突顯了給藥形式的重要性。這些劑型經過不斷測試和最佳化，以提高患者的依從性和臨床結果。同時，開發階段細分提供了對治療成熟度的洞察，並分為 I 期和 II 期臨床試驗、III 期臨床試驗、開發後監測和臨床前試驗。這種細分不僅突顯了研究強度，而且有助於識別研發線產品的風險狀況。

基於應用的細分透過關注癌症治療、心血管疾病、糖尿病管理和荷爾蒙失調等特定治療領域，進一步細化了市場觀點。這種方法確保我們為每個應用領域提供針對市場進入、法規遵循和病人參與製化策略。按居家醫療、醫院診所、實驗室、專科診所等最終用戶進行細分，在使產品定位與客戶需求和業務現實保持一致方面發揮著至關重要的作用。將這些不同的細分領域整合到整體分析中，將使相關人員能夠更好地預測市場機會並解決臨床創新與商業性可行性之間的複雜交互作用。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 越來越多的慢性疾病需要創新的口服蛋白質療法
      • 隨著營養意識的增強，口服蛋白質和胜肽補充劑的需求正在上升
    • 限制因素
      • 擔心嚴重的副作用
    • 機會
      • 製藥和生物技術合作推進口服蛋白質療法
      • 大環肽開發的新焦點
    • 任務
      • 影響全球新型口服蛋白質療法核准流程的監管障礙
  • 市場區隔分析
    • 產品類型：針對骨骼代謝紊亂和第 2 型糖尿病的胜肽療法需求不斷成長
    • 配方：膠囊配方由於易於給藥且能夠保護敏感的生物化合物而越來越受到青睞。
    • 開發階段：探索口服蛋白質和胜肽的發展階段多樣性
    • 應用：癌症治療中對口服蛋白質和胜肽的需求不斷增加，以提高患者的依從性
    • 最終用戶：居家照護環境中消費者對口服蛋白質和胜肽的偏好日益成長
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

6. 口服蛋白質和胜肽市場（依產品類型）

  • 介紹
  • 胰島素類蛋白質
    • 結合胰島素製劑
    • 長效胰島素類似物
    • 速效胰島素類似物
    • 重組人類胰島素
  • 胜肽治療方法
    • 以抑鈣素為基礎的治療方法
    • Glucagon-Like Peptide-1受體促效劑
    • 加壓素類似物

7. 口服蛋白質和胜肽市場（按配方）

  • 介紹
  • 膠囊劑型
  • 液體製劑
  • 粉末製劑
  • 錠劑配方

8. 口服蛋白質和胜肽市場（依發展階段）

  • 介紹
  • I期和II期臨床試驗
  • III期臨床試驗
  • 上市後研究
  • 臨床前研究

9. 口服蛋白質和胜肽市場（依應用）

  • 介紹
  • 癌症治療
  • 心血管疾病
  • 糖尿病管理
  • 荷爾蒙失調

第 10 章。口服蛋白質和胜肽市場（按最終用戶）

  • 介紹
  • 居家照護
  • 醫院和診所
  • 實驗室
  • 專科診所

11.美洲口服蛋白質和胜肽市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太地區口服蛋白質和胜肽市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲口服蛋白質和胜肽市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023年市場佔有率分析
  • 2023年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • AbbVie Inc.
  • Amgen Inc.
  • Amryt Pharma plc
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Entera Bio Ltd. by DNA Biomedical Solutions
  • F. Hoffmann-La Roche AG
  • Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • PeptiDream Inc.
  • Pfizer, Inc.
  • Protagonist Therapeutics, Inc.
  • Proxima Concepts Limited
  • Rani Therapeutics, LLC
  • Sanofi SA
  • Tarsa Therapeutics, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zealand Pharma A/S
Product Code: MRR-036C5CF3B4AA

The Oral Proteins & Peptides Market was valued at USD 6.10 billion in 2023 and is projected to grow to USD 6.89 billion in 2024, with a CAGR of 13.27%, reaching USD 14.60 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 6.10 billion
Estimated Year [2024] USD 6.89 billion
Forecast Year [2030] USD 14.60 billion
CAGR (%) 13.27%

Oral proteins and peptides have emerged as a focal point in the evolving landscape of therapeutics, offering transformative advantages in disease management and patient adherence. In recent years, significant advances in biotechnology and formulation science have paved the way for these molecules to transcend traditional administration barriers. There is an increasing emphasis on developing robust oral delivery systems that not only ensure bioavailability, but also enhance patient comfort and compliance. As research deepens and technology evolves, the market is witnessing a surge in interest from pharmaceutical developers, healthcare providers, and investors alike.

This comprehensive review details the current state of the market while also offering insights on future growth trajectories. It navigates through key trends, examines innovative formulation strategies, and evaluates the impact of regulatory frameworks on market expansion. The analysis is framed within an environment marked by rapid technological advancement and a global push for more effective, patient-centric therapies. This discussion is aimed at stakeholders who are known for their commitment to evidence-based decision-making and strategic market interventions. With evolving patient needs driving demand, the oral proteins and peptides market is set for disruptive breakthroughs that are poised to redefine treatment paradigms and optimize therapeutic outcomes.

From a strategic perspective, this document serves as an invaluable intellectual hub, offering data-backed insights and detailed qualitative analyses that help elucidate market behavior. The insights provided focus on integrating clinical advances and market strategies to address unmet medical needs. Ultimately, the synthesis of these insights sets the stage for a transformative journey, emphasizing the importance of aligning research, innovation, and commercialization activities in a tightly interconnected market.

Transformative Shifts in the Market Landscape and Their Strategic Implications

Over the past few years, the market for oral proteins and peptides has experienced transformative shifts, driven by rapid scientific breakthroughs and realignment of global healthcare priorities. Recent innovations in drug delivery systems have challenged the long-standing reliance on parenteral administration by introducing promising alternatives that effectively combine convenience with efficacy. This evolution is underpinned by a renewed focus on patient-centric approaches, advanced biotechnology, and strategic partnerships between research institutions and the pharmaceutical industry.

The advent of novel encapsulation techniques, improvements in peptide stability, and refinements in oral absorption enhancements are central to this transformation. Regulatory agencies are increasingly adapting their frameworks to accommodate breakthrough therapies, thereby accelerating approvals and fostering an environment that is receptive to innovation. In parallel with these technological advancements, market stakeholders have begun to reorient their strategies toward the development of integrated solutions that address both clinical requirements and economic sustainability. Decision-makers are now leveraging predictive analytics, big data, and risk-based monitoring to streamline research and development pipelines while minimizing time-to-market.

Additionally, the market has seen a significant realignment with respect to global investment flows, where emphasis is placed on targeting emerging therapeutic areas and underserved patient segments. As a result, traditional market players are compelled to rethink their operational frameworks and pursue dynamic, flexible business models. This shift is not merely an incremental improvement; it signifies a paradigm change that is redefining competitive strategies and forging new value propositions in clinical practice. In this environment, a forward-thinking approach, anchored in robust research and seamless execution, is essential to harnessing the benefits of these transformative changes.

Key Segmentation Insights Shaping Product Development and Market Strategy

A nuanced understanding of market segmentation underpins strategic planning and product development in the oral proteins and peptides space. The market is rigorously analyzed based on multiple dimensions, each yielding critical insights into its structure and growth potential. Firstly, product type segmentation distinguishes between Insulin-Based Proteins and Peptide Therapeutics. Further intricacies within this category reveal sub-segments such as Combination Insulin Products, Long-Acting Insulin Analogues, Rapid-Acting Insulin Analogues, and Recombinant Human Insulin, as well as segments corresponding to Calcitonin-Based Therapies, Glucagon-Like Peptide-1 Receptor Agonists, and Vasopressin Analogs. This detailed partitioning facilitates a deep dive into therapeutic efficacy, market penetration, and innovation trends.

The market is also segmented on the basis of formulation, where the importance of delivery format is underscored by the range of options available, such as Capsule Formulations, Liquid Formulations, Powder Formulations, and Tablet Formulations. These formats are continuously tested and optimized to improve patient compliance and clinical outcomes. In parallel, the development stage segmentation offers insights into the maturity level of therapeutics, categorized into Phase I & II Clinical Trials, Phase III Clinical Trials, Post-Market Surveillance, and Preclinical Studies. This segmentation not only highlights the research intensity but also aids in identifying the risk profile of pipeline products.

Application-based segmentation further refines the market perspective by focusing on specific therapeutic areas such as Cancer Treatment, Cardiovascular Diseases, Diabetes Management, and Hormonal Disorders. This approach ensures that each application area receives tailored strategies for market entry, regulatory compliance, and patient engagement. The segmentation based on end-user, which includes Home Care Settings, Hospitals & Clinics, Research Laboratories, and Specialty Clinics, plays a pivotal role in aligning product positioning to customer needs and operational realities. By integrating these various segmentation dimensions into a comprehensive analysis, stakeholders can better forecast market opportunities and address the complex interplay between clinical innovation and commercial viability.

Based on Product Type, market is studied across Insulin-Based Proteins and Peptide Therapeutics. The Insulin-Based Proteins is further studied across Combination Insulin Products, Long-Acting Insulin Analogues, Rapid-Acting Insulin Analogues, and Recombinant Human Insulin. The Peptide Therapeutics is further studied across Calcitonin-Based Therapies, Glucagon-Like Peptide-1 Receptor Agonists, and Vasopressin Analogs.

Based on Formulation, market is studied across Capsule Formulations, Liquid Formulations, Powder Formulations, and Tablet Formulations.

Based on Development Stage, market is studied across Phase I & II Clinical Trials, Phase III Clinical Trials, Post-Market Surveillance, and Preclinical Studies.

Based on Application, market is studied across Cancer Treatment, Cardiovascular Diseases, Diabetes Management, and Hormonal Disorders.

Based on End-User, market is studied across Home Care Settings, Hospitals & Clinics, Research Laboratories, and Specialty Clinics.

Key Regional Insights Illuminating Global Market Dynamics

The regional breakdown of the oral proteins and peptides market provides critical insight into localized trends and growth potentials. In the Americas, the market benefits from robust research ecosystems, substantial investment in biotechnology, and favorable regulatory environments. These factors create a fertile ground for rapid innovation and large-scale market adoption. Meanwhile, the combination of mature healthcare infrastructures and evolving patient needs in Europe, the Middle East, and Africa stimulates adoption of advanced therapeutic strategies. The region's diverse landscape supports both cutting-edge research and a gradual shift towards patient-focused therapy.

In the Asia-Pacific region, economic growth and expanding healthcare access are driving increased investments in pharmaceutical research and development. This dynamic span fosters an environment where emerging innovations in oral delivery systems are translated rapidly into clinical applications. The region is witnessing a growing enthusiasm towards integrating advanced therapeutic solutions into routine care, driven by rising healthcare awareness and proactive government policies. Each region, with its unique socio-economic and regulatory framework, influences the overall dynamics of the market. The interplay between regional strengths and market challenges provides a multi-faceted view of the global landscape, reinforcing the fact that geographical nuances are integral to strategic planning and market penetration efforts.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights Highlighting Industry Trailblazers and Innovators

The landscape of oral proteins and peptides is shaped by a network of industry-leading companies that are at the forefront of scientific and commercial innovation. Prominent players such as AbbVie Inc. and Amgen Inc. are renowned for their strong investment in research and a robust portfolio of advanced therapeutics. Companies like Amryt Pharma plc and Astellas Pharma Inc. leverage niche expertise to carve out significant market opportunities within specialized therapeutic areas.

Similarly, multinational corporations including AstraZeneca PLC and Boehringer Ingelheim International GmbH are redefining industry standards through strategic investments in R&D and partnerships that streamline the drug development process. Other innovators such as Catalent, Inc. and Entera Bio Ltd. by DNA Biomedical Solutions are noted for their state-of-the-art manufacturing capabilities and technological prowess that drive the efficient translation of research findings into market-ready products. Meanwhile, reputable names like F. Hoffmann-La Roche AG and Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital bring in a wealth of global experience and a strong commitment to patient-centric solutions. Johnson & Johnson Services, Inc., Merck KGaA, and Novartis AG contribute to the competitive landscape through expansive research networks and consolidated market presence, while Novo Nordisk A/S and Oramed Pharmaceuticals Inc. push forward the frontier in treatment innovation. Emerging companies such as PeptiDream Inc., Pfizer, Inc., Protagonist Therapeutics, Inc., Proxima Concepts Limited, Rani Therapeutics, LLC, Sanofi S.A., Tarsa Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Zealand Pharma A/S complete the mosaic of global leaders whose collective drive for excellence and innovation has ushered in new paradigms in the oral proteins and peptides market.

These companies not only invest heavily in research and development but are also adept at navigating complex regulatory environments and logistical challenges. Their strategic initiatives range from aggressive expansion into emerging markets to pioneering partnerships that leverage complementary expertise, thus ensuring a steady pipeline of innovative products designed for higher efficacy and improved patient outcomes.

The report delves into recent significant developments in the Oral Proteins & Peptides Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Amryt Pharma plc, Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, Boehringer Ingelheim International GmbH, Catalent, Inc., Entera Bio Ltd. by DNA Biomedical Solutions, F. Hoffmann-La Roche AG, Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital, Johnson & Johnson Services, Inc., Merck KGaA, Novartis AG, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., PeptiDream Inc., Pfizer, Inc., Protagonist Therapeutics, Inc., Proxima Concepts Limited, Rani Therapeutics, LLC, Sanofi S.A., Tarsa Therapeutics, Inc., Teva Pharmaceutical Industries Ltd., and Zealand Pharma A/S. Actionable Recommendations for Industry Leaders to Capitalize on Market Opportunities

Industry leaders are encouraged to adopt a proactive and integrated approach to capturing market opportunities in the evolving oral proteins and peptides space. It is essential to intensify investments in advanced drug delivery systems as part of dedicated R&D initiatives, particularly focusing on enhancing bioavailability and patient compliance. Leaders should re-assess current portfolio strategies with a view toward diversification across multiple segmentation dimensions, such as product type, formulation, development stage, application, and end-user. This holistic strategy ensures that resources are optimally allocated towards both innovation and market expansion.

Embracing digital transformation tools can further streamline research and market analysis, enabling predictive modeling and more precise forecasting of clinical outcomes and market trends. Companies should consider collaborating with digital health startups and leveraging big data analytics to inform product development decisions and improve operational efficiencies. Additionally, pursuing strategic alliances and partnerships, whether through mergers, acquisitions, or research collaborations, could significantly mitigate risk while enhancing the flow of technological innovation. This approach not only broadens the scope for breakthrough research but also shortens the time to market for novel therapeutics.

In parallel, market leaders must remain agile in navigating evolving regulatory landscapes. A continuous dialogue with regulatory bodies, coupled with proactive compliance and robust quality control systems, will be critical to overcoming barriers and expediting market entry. In this highly competitive environment, it is also advisable to invest in building a flexible yet resilient supply chain to support rapid scaling and distribution of new products. Ultimately, adopting an integrated strategy that emphasizes innovation, collaboration, and operational excellence will enhance a company's ability to capitalize on the emerging opportunities in the oral proteins and peptides market.

Conclusion: Harnessing Innovation and Strategic Alliances to Drive Future Growth

In summary, the oral proteins and peptides market is undergoing a period of significant transformation. In light of rapid technological progress, shifting consumer expectations, and dynamic regulatory environments, the market presents promising growth trajectories and an array of opportunities for stakeholders worldwide. Detailed analysis indicates that diversified segmentation - spanning from product types and formulations to clinical trial phases and application domains - provides a comprehensive framework for understanding market intricacies. Regional nuances further corroborate that tailored strategies are essential to address localized challenges and leverage unique market strengths.

The insights outlined in this summary reflect a blend of cutting-edge research and real-world strategic initiatives. They underscore the importance of innovation, improved clinical practices, and adaptive operational models in overcoming market uncertainties. As technological advancements continue to push the boundaries of what is clinically possible, the integration of these insights into business strategy is key to achieving sustained growth and competitive advantage. The journey forward will depend on the ability of industry leaders to forge strategic alliances, embrace new technologies, and continuously adapt to an evolving market landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases demanding innovative oral protein therapeutics
      • 5.1.1.2. Growing need for oral protein and peptide supplements with growing nutritional awareness
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with significant side effects
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborative partnerships between pharma and biotech companies for advancing oral protein therapies
      • 5.1.3.2. Emerging focus on the development of macrocyclic peptides
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory hurdles affecting the approval processes for new oral protein-based therapeutics globally
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Increasing need for peptide therapeutics targeting bone metabolism disorders and Type 2 diabetes
    • 5.2.2. Formulation: Growing preferences for capsule formulations owing to their ease of administration and ability to protect sensitive biological compounds
    • 5.2.3. Development Stage: Exploring diversities across developmental stages in oral proteins & peptides
    • 5.2.4. Application: Growing demand for oral proteins and peptides in cancer treatment for enhancing patient compliance
    • 5.2.5. End-User: Rising consumer preference for oral proteins and peptides in home care settings
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oral Proteins & Peptides Market, by Product Type

  • 6.1. Introduction
  • 6.2. Insulin-Based Proteins
    • 6.2.1. Combination Insulin Products
    • 6.2.2. Long-Acting Insulin Analogues
    • 6.2.3. Rapid-Acting Insulin Analogues
    • 6.2.4. Recombinant Human Insulin
  • 6.3. Peptide Therapeutics
    • 6.3.1. Calcitonin-Based Therapies
    • 6.3.2. Glucagon-Like Peptide-1 Receptor Agonists
    • 6.3.3. Vasopressin Analogs

7. Oral Proteins & Peptides Market, by Formulation

  • 7.1. Introduction
  • 7.2. Capsule Formulations
  • 7.3. Liquid Formulations
  • 7.4. Powder Formulations
  • 7.5. Tablet Formulations

8. Oral Proteins & Peptides Market, by Development Stage

  • 8.1. Introduction
  • 8.2. Phase I & II Clinical Trials
  • 8.3. Phase III Clinical Trials
  • 8.4. Post-Market Surveillance
  • 8.5. Preclinical Studies

9. Oral Proteins & Peptides Market, by Application

  • 9.1. Introduction
  • 9.2. Cancer Treatment
  • 9.3. Cardiovascular Diseases
  • 9.4. Diabetes Management
  • 9.5. Hormonal Disorders

10. Oral Proteins & Peptides Market, by End-User

  • 10.1. Introduction
  • 10.2. Home Care Settings
  • 10.3. Hospitals & Clinics
  • 10.4. Research Laboratories
  • 10.5. Specialty Clinics

11. Americas Oral Proteins & Peptides Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Oral Proteins & Peptides Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Oral Proteins & Peptides Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. CordenPharma's EUR 900 million investment aims to transform peptide manufacturing across the US and Europe
    • 14.3.2. Glanbia Nutritionals revolutionizes collagen supplementation with the launch of fast-absorbing Collameta
    • 14.3.3. Incyte expands inflammation portfolio with Escient acquisition, introducing novel oral MRGPR antagonists
    • 14.3.4. Johnson & Johnson achieves promising phase II results with JNJ-2113, a groundbreaking oral peptide for plaque psoriasis
    • 14.3.5. Orbis Medicines revolutionizes oral peptide drug delivery with EUR 26 million funding to enhance patient experience
    • 14.3.6. Novartis acquisition of MorphoSys AG strengthens oncology pipeline with focus on oral proteins and peptides
    • 14.3.7. Innovative partnership between Vivtex and AI Proteins aims to revolutionize oral therapies for inflammation
  • 14.4. Strategy Analysis & Recommendation
    • 14.4.1. AstraZeneca PLC
    • 14.4.2. Johnson & Johnson Services, Inc.
    • 14.4.3. Novo Nordisk A/S
    • 14.4.4. Novartis AG

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Amryt Pharma plc
  • 4. Astellas Pharma Inc.
  • 5. AstraZeneca PLC
  • 6. Biocon Limited
  • 7. Boehringer Ingelheim International GmbH
  • 8. Catalent, Inc.
  • 9. Entera Bio Ltd. by DNA Biomedical Solutions
  • 10. F. Hoffmann-La Roche AG
  • 11. Hunan Huateng Pharmaceutical Co., Ltd. by Tasly Capital
  • 12. Johnson & Johnson Services, Inc.
  • 13. Merck KGaA
  • 14. Novartis AG
  • 15. Novo Nordisk A/S
  • 16. Oramed Pharmaceuticals Inc.
  • 17. PeptiDream Inc.
  • 18. Pfizer, Inc.
  • 19. Protagonist Therapeutics, Inc.
  • 20. Proxima Concepts Limited
  • 21. Rani Therapeutics, LLC
  • 22. Sanofi S.A.
  • 23. Tarsa Therapeutics, Inc.
  • 24. Teva Pharmaceutical Industries Ltd.
  • 25. Zealand Pharma A/S

LIST OF FIGURES

  • FIGURE 1. ORAL PROTEINS & PEPTIDES MARKET MULTI-CURRENCY
  • FIGURE 2. ORAL PROTEINS & PEPTIDES MARKET MULTI-LANGUAGE
  • FIGURE 3. ORAL PROTEINS & PEPTIDES MARKET RESEARCH PROCESS
  • FIGURE 4. ORAL PROTEINS & PEPTIDES MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ORAL PROTEINS & PEPTIDES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. ORAL PROTEINS & PEPTIDES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ORAL PROTEINS & PEPTIDES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ORAL PROTEINS & PEPTIDES MARKET DYNAMICS
  • TABLE 7. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COMBINATION INSULIN PRODUCTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LONG-ACTING INSULIN ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RAPID-ACTING INSULIN ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RECOMBINANT HUMAN INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CALCITONIN-BASED THERAPIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY VASOPRESSIN ANALOGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CAPSULE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY LIQUID FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POWDER FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY TABLET FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE I & II CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PHASE III CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY POST-MARKET SURVEILLANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CANCER TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 117. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 124. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. JAPAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 131. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. MALAYSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 138. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. PHILIPPINES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 145. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. SINGAPORE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 152. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. SOUTH KOREA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 159. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. TAIWAN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 166. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. THAILAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 173. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. VIETNAM ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 188. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. DENMARK ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 195. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. EGYPT ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 202. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. FINLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 209. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. FRANCE ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 216. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. GERMANY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 223. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. ISRAEL ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 230. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. ITALY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 237. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. NETHERLANDS ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 244. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. NIGERIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 251. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 252. NORWAY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 258. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. POLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 265. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. QATAR ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 272. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. RUSSIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 280. SAUDI ARABIA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 286. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 293. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 294. SPAIN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 300. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 301. SWEDEN ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 307. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 308. SWITZERLAND ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 314. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 315. TURKEY ORAL PROTEINS & PEPTIDES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY INSULIN-BASED PROTEINS, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY PEPTIDE THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED ARAB EMIRATES ORAL PROTEINS & PEPTIDES MARKET SIZE,